AbbVie (ABBV) investors who purchased shares during periods of market pessimism and uncertainty have historically outperformed those who bought on headlines of positive drug approvals. Data indicates that buying during the 2019 Allergan selloff yielded a 449% return, significantly surpassing the 357% return for investors who entered the market following Skyrizi's approval in April 2019. This pattern suggests that good news often coincides with higher entry prices, potentially trapping buyers who fail to recognize the valuation implications of immediate positive catalysts. The company continues to execute its strategy of replacing blockbuster revenue with new immunology and oncology assets. Second-quarter 2026 sales for Skyrizi reached $5.51 billion, a 24.4% increase, while Rinvoq sales grew 24.5% to $2.53 billion. Neuroscience revenue also expanded by 20.3% to $3.23 billion in the same period, demonstrating diversification beyond its primary reliance on Humira as that product faces a steep decline following biosimilar competition. AbbVie has successfully navigated the transition from its spinoff in 2013 and the subsequent Allergan acquisition, which closed in May 2020. The company is now focused on managing the 'revenue cliff' associated with Humira's expiration while leveraging new products like Imbruvica and recent ImmunoGen acquisitions to drive growth. Management expects an injectable form of Skyrizi for Crohn's disease to boost sales starting in early 2027, alongside adjusted EPS guidance for 2026 ranging between $13.76 and $13.96.